Literature DB >> 10757394

Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made.

J I Epstein.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10757394     DOI： 10.1097/00000478-200004000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN： 0147-5185            Impact factor:   6.394


× No keyword cloud information.
  28 in total

Review 1.  Histopathology reporting of prostate needle biopsies. 2005 update.

Authors:  Rodolfo Montironi; Remigio Vela Navarrete; Antonio Lopez-Beltran; Roberta Mazzucchelli; Gregor Mikuz; Aldo V Bono
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

Review 2.  [The value of the modified Gleason grading system of prostate adenocarcinoma in routine urological diagnostics].

Authors:  B Helpap; L Egevad
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

Review 3.  Current practice of Gleason grading of prostate carcinoma.

Authors:  Antonio Lopez-Beltran; Gregor Mikuz; Rafael J Luque; Roberta Mazzucchelli; Rodolfo Montironi
Journal:  Virchows Arch       Date:  2005-11-23       Impact factor: 4.064

4.  Conflicting insights into the role of watchful waiting in the management of adenocarcinoma of the prostate.

Authors:  Danil V Makarov; Alan W Partin
Journal:  Rev Urol       Date:  2006

5.  The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens.

Authors:  Burkhard Helpap; Lars Egevad
Journal:  Virchows Arch       Date:  2006-11-08       Impact factor: 4.064

6.  Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.

Authors:  Ying Huang; Sumit Isharwal; Alexander Haese; Felix K H Chun; Danil V Makarov; Ziding Feng; Misop Han; Elizabeth Humphreys; Jonathan I Epstein; Alan W Partin; Robert W Veltri
Journal:  BJU Int       Date:  2010-09-28       Impact factor: 5.588

Review 7.  Current perspectives on Gleason grading of prostate cancer.

Authors:  Kenneth A Iczkowski; M Scott Lucia
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

8.  The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.

Authors:  Al B Barqawi; Ruslan Turcanu; Eduard J Gamito; Scott M Lucia; Colin I O'Donnell; E David Crawford; David D La Rosa; Francisco G La Rosa
Journal:  Int J Clin Exp Pathol       Date:  2011-06-12

9.  Reduced glycosylation of α-dystroglycans on carcinoma cells contributes to formation of highly infiltrative histological patterns in prostate cancer.

Authors:  Hisashi Shimojo; Motohiro Kobayashi; Takayuki Kamigaito; Yasuyo Shimojo; Minoru Fukuda; Jun Nakayama
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

10.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.